Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy
PHASE1CompletedINTERVENTIONAL
Timeline
Start Date
June 30, 1998
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL
aldesleukin
BIOLOGICAL
therapeutic autologous lymphocytes
BIOLOGICAL
therapeutic tumor infiltrating lymphocytes
Trial Locations (1)
20892
Medicine Branch, Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00019357 - Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy | Biotech Hunter | Biotech Hunter